ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, announced that it will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014, at 8:40 a.m. Eastern Time in New York City. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares after opening at $22.92 moved to $23.43 on last trade day and at the end of the day closed at $21.35. Company price to sales ratio in past twelve months was calculated as 1892.39 and price to cash ratio as 11.20. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) showed a negative weekly performance of -5.74%.
XOMA Corp (NASDAQ:XOMA) recorded total revenues of $35.5 million for the twelve months ended December 31, 2013, compared with $33.8 million during the same period of 2012. XOMA Corp (NASDAQ:XOMA) shares fell -5.49% in last trading session and ended the day on $4.65. XOMA return on assets is -152.10%. XOMA Corp (NASDAQ:XOMA) yearly performance is 36.76%.
Kandi Technologies Group Inc. (NASDAQ:KNDI) announced on Tuesday that it has closed the registered direct placement with two investors and raised approximately $11.05 million from selling its shares of common stock for $18.24 per share. Kandi Technologies Group Inc. (NASDAQ:KNDI) shares moved down -10.49% in last trading session and was closed at $14.08, while trading in range of $13.63 – $15.89. Kandi Technologies Group Inc. (NASDAQ:KNDI) year to date (YTD) performance is 19.42%.
Investment analysts at Citigroup Inc. began coverage on shares of FireEye (NASDAQ:FEYE) in a note issued to investors on Friday, TheFlyOnTheWall.com reports. The firm set a “neutral” rating and a $60.00 price target on the stock. Citigroup Inc.’s price objective would suggest a potential upside of 9.37% from the stock’s previous close. FireEye Inc. (NASDAQ:FEYE) weekly performance is -20.62%. On last trading day company shares ended up $50.36. FireEye Inc. (NASDAQ:FEYE) distance from 50-day simple moving average (SMA50) is -30.95%. Analysts mean target price for the company is $77.00.